Making the Call in Heart Failure
Multidimensional Outcomes With SGLT2 Inhibitors
Meeting Slides
Clinical Practice Guidelines
2022 AHA/ACC/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Heidenreich PA, et al. Circulation. 2022;145(18):e895-e1032.
2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction.
Maddox TM, et al. J Am Coll Cardiol. 2021;77(6):772-810.
2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee.
Das, et al. J Am Coll Cardiol. 2020;76(9):1117-1145.
Clinician Resources
American College of Cardiology, Global CV Institute website, Heart Failure: Applying the Guidelines
Suggested Readings
Heart disease and stroke statistics-2020 update: a report from the American Heart Association.
Virani et al. Circulation. 2020;141(9):e139-e596.
How should we sequence the treatments for heart failure and a reduced ejection fraction?: a redefinition of evidence-based medicine.
McMurray et al. Circulation. 2021;143(9):875-877.
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.
Zinman B, et al. N Engl J Med. 2015;373(22):2117-2128.
Canagliflozin and cardiovascular and renal events in type 2 diabetes.
Neal B, et al. N Engl J Med. 2017;377(7):644-657.
Dapagliflozin and cardiovascular outcomes in type 2 diabetes.
Wiviott SD, et al. N Engl J Med. 2019;380(4):347-357.
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.
Perkovic V, et al. N Engl J Med. 2019;380(24):2295-2306.
Cardiovascular outcomes with ertugliflozin in type 2 diabetes.
Cannon CP, et al. N Engl J Med. 2020;383(15):1425-1435.
Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis.
McGuire D, et al. JAMA Cardiol. 2021;6(2):148–158.
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Zannad F, et al. Lancet. 2020;396:819-829.
Empagliflozin in heart failure with a preserved ejection fraction.
Anker et al. N Engl J Med. 2021;385(16):1451-1461.
Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction.
Solomon et al. N Engl J Med. 2022;387(12):1089-1098.
Multidimensional Outcomes with SGLT2 Inhibitors
Multidimensional Outcomes with SGLT2 Inhibitors
Relevant Resources
Mechanism-Based Strategies to Achieve Patient-Centered Care
Patient-Centered Management of Hyperglycemia in Primary Care
Integrating GLP-1 Receptor Agonists Into Multimodal Treatment Regimens
Translating Research Into Practice
Translating Reseach Into Practice
Overcoming Diagnostic Barriers and Optimizing Long-Term Patient Outcomes
Discussions and Debates Around GLP-1 Receptor Agonists
Evolving Roles of GLP-1 Receptor Agonists
Individualizing Evidence-Based Care
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Best Practices in Diagnosis and Management
New Strategies for Insulin Replacement Therapy
Consensus and Controversies Around Intensifying Noninsulin Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
An Evolving Role for Combinations of Injectable Antihyperglycemic Therapies
Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management
Evolving Roles of GLP-1 Receptor Agonists
Looking Beyond Hemoglobin A1c
What You Need to Know
Mechanistic Insights and Evolving Treatment Options
Implications for PCSK9 Inhibitors in Clinical Practice
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Reducing LDL-C and a Lifetime of Cardiovascular Risk
New Avenues to Improve Patient Outcomes
Best Practices for Screening, Diagnosis, and Management
